Ignite Creation Date:
2024-07-17 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06467617
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-21
First Post:
2024-06-13
Brief Title:
Adebrelimab Plus Chemo and Recaticimab Perioperative Treatment for Resectable NSCLC
Sponsor:
Beijing Chest Hospital Capital Medical University
Organization:
Beijing Chest Hospital Capital Medical University
Study Overview
Official Title:
Adebrelimab Plus Albumin-bound Paclitaxel Carboplatin and Recaticimab Perioperative Treatment for Resectable NSCLC a Phase II Clinical Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Current studies confirmed that the immune peri-operative treatment with combination chemotherapy curative effect and safety of resectable NSCLC but its short-term curative effect and long-term survival benefit remains to be further improved to explore the new way of immune combination therapy
Experimental study showed that the inhibition of PCSK9 could significantly increase in tumor cells of the immune response in mice inhibit the PCSK9 enhanced anti-tumor immune response of mice can be further coordinate with immune checkpoint therapy forming a lasting anti-tumor immune effect
There are no reports on the peri-operative treatment of immune combined with chemotherapy and PCSK-9 inhibitors in patients with resectable NSCLC
Based on the above the aim of this study is to explore the efficacy and safety of Adebrelimab combined with recaticimab and chemotherapy in the peri-operative treatment of patients with resectable NSCLC
Experimental study showed that the inhibition of PCSK9 could significantly increase in tumor cells of the immune response in mice inhibit the PCSK9 enhanced anti-tumor immune response of mice can be further coordinate with immune checkpoint therapy forming a lasting anti-tumor immune effect
There are no reports on the peri-operative treatment of immune combined with chemotherapy and PCSK-9 inhibitors in patients with resectable NSCLC
Based on the above the aim of this study is to explore the efficacy and safety of Adebrelimab combined with recaticimab and chemotherapy in the peri-operative treatment of patients with resectable NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None